89bio’s Breakthrough: 48-Week Results from Pegozafermin Phase 2b Trial in MASH Show Promising Efficacy and Safety at EASL Congress

Published | Modified May 22, 2024
CSIMarket Newsroom | CSIMarket.com

89bio Presents 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress’

89bio, a clinical-stage biopharmaceutical company, has announced the presentation of the 48-week data from its ENLIVEN Phase 2b trial of Pegozafermin at the European Association for the Study of the Liver (EASL) International Liver Congress. Pegozafermin is under investigation as a potential treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The poster presentation

Source for this article: Based on 89bio Inc ’s official statement

For details on how CSIMarket validates financial and corporate news, please review our Editorial Standards & Fact-Checking Policy .

Comments

Comments are available to active subscribers. Subscribe or Log in.

Get the full CSIMarket dataset: Subscribe API License